Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 5/2010

01-10-2010

The Impact of Obstructive Sleep Apnea on Chronic Kidney Disease

Authors: Gbemisola A. Adeseun, Sylvia E. Rosas

Published in: Current Hypertension Reports | Issue 5/2010

Login to get access

Abstract

Obstructive sleep apnea (OSA) is an important clinical problem in the chronic kidney disease (CKD) population. OSA is associated with hypoxemia and sleep fragmentation, which activates the sympathetic nervous system, the renin-angiotensin-aldosterone system, alters cardiovascular hemodynamics, and results in free radical generation. In turn, a variety of deleterious processes such as endothelial dysfunction, inflammation, platelet aggregation, atherosclerosis, and fibrosis are triggered, predisposing individuals to adverse cardiovascular events and likely renal damage. Independent of obesity, OSA is associated with glomerular hyperfiltration and may be an independent predictor of proteinuria, a risk factor for CKD progression. OSA is also associated with hypertension, another important risk factor for CKD progression, particularly proteinuric CKD. OSA may mediate renal damage via several mechanisms, and there is a need to better elucidate the impact of OSA on incident renal disease and CKD progression.
Literature
1.
Kapur VK, Redline S, Nieto FJ, et al.: The relationship between chronically disrupted sleep and healthcare use. Sleep 2002, 25:289–296.PubMed
2.
Foley DJ, Monjan A, Simonsick EM, et al.: Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. Sleep 1999, 22(Suppl 2):S366–S372.PubMed
3.
He J, Kryger MH, Zorick FJ, et al.: Mortality and apnea index in obstructive sleep apnea. Experience in 385 male patients. Chest 1988, 94:9–14.
4.
Nieto FJ, Young TB, Lind BK, et al.: Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000, 283:1829–1836.CrossRefPubMed
5.
Shahar E, Whitney CW, Redline S, et al.: Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001, 163:19–25.PubMed
6.
Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force [no authors listed]. Sleep 1999, 22:667–689.
7.
Kuhlmann U, Bormann FG, Becker HF: Obstructive sleep apnoea: clinical signs, diagnosis and treatment. Nephrol Dial Transplant 2009, 24:8–14.CrossRefPubMed
8.
Young T, Skatrud J, Peppard PE: Risk factors for obstructive sleep apnea in adults. JAMA 2004, 291:2013–2016.CrossRefPubMed
9.
Young T, Palta M, Dempsey J, et al.: The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993, 328:1230–1235.CrossRefPubMed
10.
Young T, Evans L, Finn L, Palta M: Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep 1997, 20:705–706.PubMed
11.
• Sim JJ, Rasgon SA, Kujubu DA, et al.: Sleep apnea in early and advanced chronic kidney disease: Kaiser Permanente Southern California cohort. Chest 2009, 135:710–716. This is an important article that explores that relationship between OSA and early CKD.CrossRefPubMed
12.
Hanly P: Sleep apnea and daytime sleepiness in end-stage renal disease. Semin Dial 2004, 17:109–114.CrossRefPubMed
13.
Shayamsunder AK, Patel SS, Jain V, et al.: Sleepiness, sleeplessness, and pain in end-stage renal disease: distressing symptoms for patients. Semin Dial 2005, 18:109–118.CrossRefPubMed
14.
Unruh ML, Sanders MH, Redline S, et al.: Sleep apnea in patients on conventional thrice-weekly hemodialysis: comparison with matched controls from the Sleep Heart Health Study. J Am Soc Nephrol 2006, 17:3503–3509.CrossRefPubMed
15.
Markou N, Kanakaki M, Myrianthefs P, et al.: Sleep-disordered breathing in nondialyzed patients with chronic renal failure. Lung 2006, 184:43–49.CrossRefPubMed
16.
Unruh ML: Sleep apnea and dialysis therapies: things that go bump in the night? Hemodial Int 2007, 11:369–378.CrossRefPubMed
17.
Agrawal V, Vanhecke TE, Rai B, et al.: Albuminuria and renal function in obese adults evaluated for obstructive sleep apnea. Nephron Clin Pract 2009, 113:c140–c147.CrossRefPubMed
18.
• Fleischmann G, Fillafer G, Matterer H, et al.: Prevalence of chronic kidney disease in patients with suspected sleep apnoea. Nephrol Dial Transplant 2010, 25:181–186. This is a recent study that examines the epidemiology of CKD among individuals with OSA.CrossRefPubMed
19.
Kinebuchi S, Kazama JJ, Satoh M, et al.: Short-term use of continuous positive airway pressure ameliorates glomerular hyperfiltration in patients with obstructive sleep apnoea syndrome. Clin Sci (Lond) 2004, 107:317–322.CrossRef
20.
Casserly LF, Chow N, Ali S, et al.: Proteinuria in obstructive sleep apnea. Kidney Int 2001, 60:1484–1489.CrossRefPubMed
21.
Serra A, Romero R, Lopez D, et al.: Renal injury in the extremely obese patients with normal renal function. Kidney Int 2008, 73:947–955.CrossRefPubMed
22.
Chaudhary BA, Sklar AH, Chaudhary TK, et al.: Sleep apnea, proteinuria, and nephrotic syndrome. Sleep 1988, 11:69–74.PubMed
23.
Sklar AH, Chaudhary BA: Reversible proteinuria in obstructive sleep apnea syndrome. Arch Intern Med 1988, 148:87–89.CrossRefPubMed
24.
Faulx MD, Storfer-Isser A, Kirchner HL, et al.: Obstructive sleep apnea is associated with increased urinary albumin excretion. Sleep 2007, 30:923–929.PubMed
25.
Peppard PE, Young T, Palta M, Skatrud J: Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000, 342:1378–1384.CrossRefPubMed
26.
Drager LF, Bortolotto LA, Figueiredo AC, et al.: Obstructive sleep apnea, hypertension, and their interaction on arterial stiffness and heart remodeling. Chest 2007, 131:1379–1386.CrossRefPubMed
27.
Blacher J, Asmar R, Djane S, et al.: Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999, 33:1111–1117.PubMed
28.
Meaume S, Benetos A, Henry OF, et al.: Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol 2001, 21:2046–2050.CrossRefPubMed
29.
• Dempsey JA, Veasey SC, Morgan BJ, O'Donnell CP: Pathophysiology of sleep apnea. Physiol Rev 2010, 90:47–112. This is an excellent review of the pathophysiology of OSA, with an emphasis on the cardiovascular consequences of OSA.CrossRefPubMed
30.
Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996, 98:1063–1068.CrossRefPubMed
31.
Aldigier JC, Kanjanbuch T, Ma LJ, et al.: Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005, 16:3306–3314.CrossRefPubMed
32.
Calhoun DA, Nishizaka MK, Zaman MA, Harding SM: Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004, 125:112–117.CrossRefPubMed
33.
Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, et al.: Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007, 131:453–459.CrossRefPubMed
34.
Agodoa LY, Appel L, Bakris GL, et al.: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285:2719–2728.CrossRefPubMed
35.
Peker Y, Kraiczi H, Hedner J, et al.: An independent association between obstructive sleep apnoea and coronary artery disease. Eur Respir J 1999, 14:179–184.CrossRefPubMed
36.
Yaggi HK, Concato J, Kernan WN, et al.: Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005, 353:2034–2041.CrossRefPubMed
37.
Punjabi NM, Newman AB, Young TB, et al.: Sleep-disordered breathing and cardiovascular disease: an outcome-based definition of hypopneas. Am J Respir Crit Care Med 2008, 177:1150–1155.CrossRefPubMed
38.
Somers VK, White DP, Amin R, et al.: Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol 2008, 52:686–717.CrossRefPubMed
39.
Budhiraja R, Parthasarathy S, Quan SF: Endothelial dysfunction in obstructive sleep apnea. J Clin Sleep Med 2007, 3:409–415.PubMed
40.
Quercioli A, Mach F, Montecucco F: Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). Sleep Breath 2010 Mar 3 [Epub ahead of print].
41.
Lattimore JL, Wilcox I, Skilton M, et al.: Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation. Thorax 2006, 61:491–495.CrossRefPubMed
42.
El Solh AA, Akinnusi ME, Baddoura FH, Mankowski CR: Endothelial cell apoptosis in obstructive sleep apnea: a link to endothelial dysfunction. Am J Respir Crit Care Med 2007, 175:1186–1191.CrossRefPubMed
43.
Schulz R, Mahmoudi S, Hattar K, et al.: Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000, 162:566–570.PubMed
44.
Yokoe T, Minoguchi K, Matsuo H, et al.: Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003, 107:1129–1134.CrossRefPubMed
45.
Schulz R, Schmidt D, Blum A, et al.: Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax 2000, 55:1046–1051.CrossRefPubMed
46.
Phillips BG, Narkiewicz K, Pesek CA, et al.: Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens 1999, 17:61–66.PubMed
47.
Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32(5 Suppl 3):S112–S119.CrossRefPubMed
48.
Schohn D, Weidmann P, Jahn H, Beretta-Piccoli C: Norepinephrine-related mechanism in hypertension accompanying renal failure. Kidney Int 1985, 28:814–822.CrossRefPubMed
49.
Sklar AH, Chaudhary BA, Harp R: Nocturnal urinary protein excretion rates in patients with sleep apnea. Nephron 1989, 51:35–38.CrossRefPubMed
50.
Mello P, Franger M, Boujaoude Z, et al.: Night and day proteinuria in patients with sleep apnea. Am J Kidney Dis 2004, 44:636–641.PubMed
Metadata
Title
The Impact of Obstructive Sleep Apnea on Chronic Kidney Disease
Authors
Gbemisola A. Adeseun
Sylvia E. Rosas
Publication date
01-10-2010
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 5/2010
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-010-0135-1

Other articles of this Issue 5/2010

Current Hypertension Reports 5/2010 Go to the issue

Invited Commentary

The Diagnosis and Management of Syncope

ReviewPaper

Hypertension in the Elderly: What Is the Goal Blood Pressure Target and How Can This Be Attained?

ReviewPaper

Masked Hypertension: Evidence of the Need to Treat

ReviewPaper

Is the Presence of Microalbuminuria a Relevant Marker of Kidney Disease?

Clinical Trial Report

Optimal Blood Pressure for a Patient with Type 2 Diabetes Mellitus: Insight from the ACCORD Study

ReviewPaper

Should All Hypertensive Dialysis Patients Receive a Blocker of the Renin-Angiotensin System?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits